EFFECTS OF ATORVASTATIN COMBINED WITH TRIMETAZIDINE ON CARDIAC FUNCTION AND SE- RUM NT-PRO BNP AND HS-CRP IN CORONARY HEART DISEASE PATIENTS WITH CHRONIC HEART FAILURE

Yang Xiaofei1, #, fu YingYing2, #, Duan feiru3, Wang ZhiYong4*

1Department of Cardiovascular Medicine, Shanxi Second Provincial People’s Hospital, No.3, Shangqin Road, Xi’an, Shaanxi, China 710005 - 2Department of Emergency, Shaanxi Provincial People’s Hospital, No.256, Youyi West Road, Beilin District, Xi ‘an, Shaanxi, China 710068 - 3Department of Tranditional Chinese Medicine, Xi’an Medical University, No.1, Xinwang Road, Xi’an, Shaanxi, China, 710021 - 4Traditional Chinese Medicine , The Second Affiliated Hospital of Xi’an Jiaotong University, No.157, Xiwu Road, Xi’an, Shaanxi, China, 710004

 Objective: To investigate the clinical efficacy of atorvastatin combined with trimetazidine in the treatment of chronic heart failure in patients with coronary heart disease and to evaluate the effects of the treatment regimen on cardiac function and serum N-terminal pro-brain natriuretic peptide (NT-proBNP) and high sensitive C-reaction protein (hs-CRP) content.

Methods: A total of 120 coronary heart disease patients with chronic heart failure from June 2016 to May 2017 were selected. The patients were randomly divided into two groups, including the atorvastatin group, in which the patients were given additional atorvastatin drug intervention (20 mg/d), and the combined treatment group, in which, the patients were treated with trimetazidine three times a day (20 mg/d). The clinical data were recorded and analyzed. By comparing the improvement inpalpitation, chest distress and angina pectoris and the improvement incardiac function in the two groups, the curative effect of chronic heart failure in patients with coronary heart disease was evaluated. Moreover, the differences of serum NT-pro BNP, hs-CRP and blood lipid levels between the two groups were analyzed.

Results: After 4 weeks of treatment, the improvement inpalpitation, chest distress and angina pectoris in the combined treatment group was significantly higher than that in the atorvastatin group, and the difference wasstatistically significant (P<0.05). The levels of serum NT-pro BNP, hs-CRP and blood lipid levels in the combined treatment group were significantly lower than those in the ator- vastatin group, and the difference was statistically significant (P<0.05).

Conclusion: Atorvastatin combined with trimetazidine significantly improved chronic heart failure and significantly reduced serum NT-pro BNP and hs-CRP levels in patients with coronary heart disease.